Printer Friendly

LIDAK SIGNS LICENSING AGREEMENT WITH CTS CHEMICAL INDUSTRIES FOR MANUFACTURE AND MARKETING OF LIDAKOL

 LA JOLLA , Calif., July 14 /PRNewswire/ -- LIDAK Pharmaceuticals (NASDAQ: LDAKA) announced today that it has signed a licensing agreement with CTS Chemical Industries Ltd. (CTS), located in Kiryat Malachi, Israel, a subsidiary of CTS LTD. of Tel Aviv. CTS will be responsible for obtaining regulatory approval of LIDAKOL(TM) and for its manufacture, promotion and distribution in Israel.
 "we are pleased to have entered into this agreement with CTS which ranks among the top five pharmaceutical marketing companies in Israel and has the experience, marketing strength and financial capability to successfully market LIDAKOL," said David H. Katz, M.D., LIDAK's president and chief executive officer. "This agreement expands our market presence for LIDAKOL in the Middle East and is another step in the implementation of our strategy to globally market our products, which began with our agreement with Brocades Pharma b.v." In that agreement, Brocades Pharma is responsible for obtaining regulatory approval of LIDAKOL and for its manufacture, promotion and distribution throughout Europe and selected other Middle Eastern countries.
 LIDAK recently initiated its third Phase II clinical trial of LIDAKOL to test the efficacy of the compound as a topical treatment for oral herpes infections (commonly known as cold sores and fever blisters). Two other Phase II clinical trials investigating topical LIDAKOL were initiated in November, 1992. One is being conducted in Europe on patients with recurrent oral herpes, and the other in the United States on patients with recurrent genital herpes.
 LIDAK Pharmaceuticals is developing therapeutic products against virally caused diseases, inflammatory disorders and cancer. The company's initial focus is on the commercialization of LIDAKOL as a treatment for herpes and other indications. The company is also developing its Large Multivalent Immunogen (LMI) technology for potential new therapies against cancer and viral diseases.
 -0- 7/14/93
 /CONTACT: Michael H. Lorber, vice president & CFO of LIDAK Pharmaceuticals, 619-558-0364; or Fern Lazar or Kate de Santis of Dewe Rogerson, 212-688-6840, for LIDAK Pharmaceutical/
 (LDAKA)


CO: LIDAK Pharmaceuticals; CTS Chemical Industries Ltd. ST: California IN: MTC SU: LIC

SH-MG -- NY070 -- 1505 07/14/93 14:39 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jul 14, 1993
Words:347
Previous Article:MICROGNOSIS ACQUIRES ASSETS OF FD CONSULTING
Next Article:RELIANCE COMPLETES SALE OF LIFE INSURANCE SUBSIDIARY
Topics:


Related Articles
LIDAK PHARMACEUTICALS AND BROCADES PHARMA ANNOUNCE LICENSE AGREEMENT
LIDAK PHARMACEUTICALS U.S. LICENSING NEGOTIATIONS TERMINATED; COMPANY POISED TO LAUNCH PHASE II CLINICAL TRIALS
LIDAK RECEIVES PATENT FOR SYSTEMIC USES OF LIDAKOL
LIDAK PHARMACEUTICALS RECEIVES EUROPEAN PATENT
LIDAK PHARMACEUTICALS AND BRISTOL-MYERS SQUIBB SIGN MULTI-NATIONAL COLLABORATIVE LICENSING AGREEMENT FOR LIDAKOL(TM)
LIDAK Reacquires International Licensing Rights To LIDAKOL(R)
LIDAK Pharmaceuticals Reports Cancellation of Bristol-Myers Squibb North American License
LIDAK Pharmaceuticals Announces Termination of Discussions With HealthMed, Inc.
LIDAK Pharmaceuticals Retains Dilenschneider Group to Direct Expanded Corporate/Investor Communications Program
LIDAK Pharmaceuticals Selects CONDEA Chemie GmbH for Manufacture of n-docosanol.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters